Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25402 | 0.89 | SCD (0.68) | SCDDCTPP1 | |
| SCHEMBL25483 | 0.88 | SCD (0.69) | SCDDCTPP1 | |
| SCHEMBL15225460 | 0.85 | SCD (0.61) | SCDDCTPP1 | |
| SCHEMBL1377032 | 0.81 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL24230 | 0.81 | SCD (0.71) | SCDDCTPP1 | |
| SCHEMBL24735 | 0.80 | SCD (0.57) | SCDDCTPP1 | |
| SCHEMBL1380562 | 0.79 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL1379383 | 0.78 | SCD (0.93) | SCDDCTPP1 | |
| SCHEMBL1377463 | 0.77 | SCD (0.75) | SCDDCTPP1 | |
| SCHEMBL24322 | 0.76 | SCD (0.49) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919496-B2 | 5-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester; metabolic disorders type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome; cardiovascular disorders | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | claimed |
| US-7919496-B2 | 5-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester; metabolic disorders type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome; cardiovascular disorders | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
| EP-2289510-A1 | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes | Xenon Pharmaceuticals Inc. (CA) | 2011-03-02 | — | — | EP | disclosed |